111 related articles for article (PubMed ID: 22329473)
1. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.
Anand A; Gunn AD; Barkay G; Karne HS; Nurnberger JI; Mathew SJ; Ghosh S
Bipolar Disord; 2012 Feb; 14(1):64-70. PubMed ID: 22329473
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works.
Lu RB; Chen SL; Lee SY; Chang YH; Chen SH; Chu CH; Tzeng NS; Lee IH; Chen PS; Yeh TL; Huang SY; Yang YK; Hong JS
Med Hypotheses; 2012 Aug; 79(2):280-3. PubMed ID: 22677298
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders.
Chouchana M; Delage C; Godin O; Fontan JE; Bellivier F; Gard S; Aubin V; Belzeaux R; Dubertret C; Haffen E; Leboyer M; Olie E; Courtet P; Polosan M; Roux P; Samalin L; Schwan R; Lefrere A; Bloch V; Etain B;
Eur Neuropsychopharmacol; 2023 Aug; 73():75-81. PubMed ID: 38465581
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus.
Brown ES; Kulikova A; Van Enkevort E; Nakamura A; Ivleva EI; Tustison NJ; Roberts J; Yassa MA; Choi C; Frol A; Khan DA; Vazquez M; Holmes T; Malone K
Neuropsychopharmacology; 2019 Dec; 44(13):2263-2267. PubMed ID: 31181564
[TBL] [Abstract][Full Text] [Related]
5. The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.
Brunner LM; Riebel M; Wein S; Koller M; Zeman F; Huppertz G; Emmer T; Eberhardt Y; Schwarzbach J; Rupprecht R; Nothdurfter C
Trials; 2024 Apr; 25(1):274. PubMed ID: 38650030
[TBL] [Abstract][Full Text] [Related]
6. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression.
Mah L; Zarate CA; Nugent AC; Singh JB; Manji HK; Drevets WC
Int J Neuropsychopharmacol; 2011 May; 14(4):545-51. PubMed ID: 21029512
[TBL] [Abstract][Full Text] [Related]
7. New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Keramatian K; Chakrabarty T; DuBow A; Saraf G; Yatham LN
Drugs; 2023 Jul; 83(10):843-863. PubMed ID: 37227597
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients.
Camardese G; Leone B; Serrani R; Walstra C; Di Nicola M; Della Marca G; Bria P; Janiri L
Neuropsychiatr Dis Treat; 2015; 11():2331-8. PubMed ID: 26396517
[TBL] [Abstract][Full Text] [Related]
9. CFC delta-beta is related with mixed features and response to treatment in bipolar II depression.
Kesebir S; Demirer RM; Tarhan N
Heliyon; 2019 Jun; 5(6):e01898. PubMed ID: 31338449
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Bourla A
N Engl J Med; 2023 Dec; 389(24):2306. PubMed ID: 38091547
[No Abstract] [Full Text] [Related]
11. Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Blay M; Bernardoff L
N Engl J Med; 2023 Dec; 389(24):2306. PubMed ID: 38091546
[No Abstract] [Full Text] [Related]
12. Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Nóbrega GC; Vasconcelos MM; Bisol LW
N Engl J Med; 2023 Dec; 389(24):2305. PubMed ID: 38091545
[No Abstract] [Full Text] [Related]
13. Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Yang TC; Kao YC; Liang CS
N Engl J Med; 2023 Dec; 389(24):2305. PubMed ID: 38091544
[No Abstract] [Full Text] [Related]
14. Adjunctive Antidepressant Maintenance in Bipolar I Depression. Reply.
Yatham LN; Wong H; Reddy YCJ;
N Engl J Med; 2023 Dec; 389(24):2306-2307. PubMed ID: 38091548
[No Abstract] [Full Text] [Related]
15. Memantine can protect against inflammation-based cognitive decline in geriatric depression.
Van Dyk K; Siddarth P; Rossetti M; Ercoli LM; Milillo MM; Lavretsky H
Brain Behav Immun Health; 2020 Dec; 9():100167. PubMed ID: 34589902
[TBL] [Abstract][Full Text] [Related]
16. Adding esketamine to lamotrigine to treat major depression: Combinatorial synergism, augmentation, or neither?
Malhi GS; Le U; Kaufmann C; Bell E
Bipolar Disord; 2024 May; ():. PubMed ID: 38782849
[No Abstract] [Full Text] [Related]
17. MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease.
Hegemann I; Sasselli C; Valeri F; Makhro A; Müller R; Bogdanova A; Manz MG; Gassmann M; Goede JS
Hemasphere; 2020 Aug; 4(4):e452. PubMed ID: 32885144
[No Abstract] [Full Text] [Related]
18. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
Smith EG; Deligiannidis KM; Ulbricht CM; Landolin CS; Patel JK; Rothschild AJ
J Clin Psychiatry; 2013 Oct; 74(10):966-73. PubMed ID: 24229746
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.
Gideons ES; Kavalali ET; Monteggia LM
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8649-54. PubMed ID: 24912158
[TBL] [Abstract][Full Text] [Related]
20. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder.
Serra G; Koukopoulos A; De Chiara L; Koukopoulos AE; Tondo L; Girardi P; Baldessarini RJ; Serra G
J Clin Psychiatry; 2015 Jan; 76(1):e91-7. PubMed ID: 25650685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
